Featured Stories

  • Resverlogix in Active Discussions with Morocco

    Resverlogix is in active discussions for COVID-19 clinical studies in Morocco involving apabetalone.

    Learn More

  • Donald McCaffrey at Benzinga All Access

    Resverlogix President & CEO Donald McCaffrey presents at Benzinga All Access conference 2021

    Learn More

  • Resverlogix: The Future of Drug Development

    Donald McCaffrey, President & CEO of Resverlogix will be featured on CEO Clips on the BNN Bloomberg channel airing October 9 & 10   © 2021 www.B-TV.com ....

    Learn More

  • Apabetalone meets primary endpoint in PAH pilot study

    Resverlogix reported that its lead drug apabetalone met its primary endpoint in a pulmonary arterial hypertension or ‘PAH’ investigator led pilot study. Watch the news...

    Learn More

  • EVERSANA & Resverlogix Discuss Partnership On PharmaVOICE Webinar

    Rohit Sood, EVP, COMPLETE Commercialization, EVERSANA / Donald McCaffrey, President & CEO, Resverlogix: Next Generation Commercial Innovation: Moving From Promise to Practice. 

    Learn More

  • Donald McCaffrey featured on Innovators with Jane King

    Donald McCaffrey, President & CEO of Resverlogix featured on Innovators with Jane King. Latest updates on the Company's COVID-19 program.

    Learn More

  • COVID-19 Program Update with Donald McCaffrey

    CEO Donald McCaffrey joined PBA à Noon, for a live webinar and Q&A, to discuss the latest developments in Resverlogix' COVID-19 program.

    Learn More

  • Health Canada Authorizes COVID-19 Clinical Study

    Resverlogix receives "No Objection Letter" from Health Canada, approving the COVID-19 Clinical Trial Application for apabetalone.

    Learn More

  • Apabetalone May Prevent Heart Damage Caused by COVID-19

    COVID-19 affects not only lung and respiratory tissue but can injure your heart as well. One study, published in the Journal of the American Medical Association, found that 78% of recently...

    Learn More

  • Balancing Epigenetics in the Treatment of Chronic Kidney Disease

    Kidneys are the body’s filtration system . They clean our blood, removing waste and helping manage blood pressure by controlling the outflow of water. Unfortunately, when these filters...

    Learn More

  • Targeting Epigenetics as a New Therapy in Vascular Disease and Dementia

    Cardiovascular disease literally means disease of the heart and blood vessels, but it can cause additional life-altering complications that we might not initially associate with the disease,...

    Learn More

  • The Faces of Cardiovascular Disease: Series Final

    This is the final article of the mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men...

    Learn More

  • The Faces of Cardiovascular Disease: Part 4

    This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...

    Learn More

  • The Faces of Cardiovascular Disease: Part 3

    This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...

    Learn More

  • The Faces of Cardiovascular Disease: Part 2

    This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...

    Learn More

  • The Faces of Cardiovascular Disease: Part 1

    This article is part of a mini-series we are calling The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of...

    Learn More

  • Apabetalone: A Relative Size Animation

    Our lead compound – apabetalone – is the first small molecule of its kind with potentially important benefits for patients with high-risk cardiovascular and other chronic diseases. But...

    Learn More

  • Resverlogix in Active Discussions with Morocco

    Resverlogix is in active discussions for COVID-19 clinical studies in Morocco involving apabetalone.